scholarly journals Periocular basal cell carcinoma - clinical perspectives

2020 ◽  
Vol 14 (1) ◽  
Author(s):  
Alena Furdova ◽  
Karolina Kapitanova ◽  
Alexandra Kollarova ◽  
Juraj Sekac
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Treatment Options ◽  
Surgical Excision ◽  
Cancer Type ◽  
Non Melanoma Skin Cancer ◽  
Periocular Region ◽  
Age Over 60 ◽  
Orbital Invasion

Basal cell carcinoma (BCC) as a non-melanoma skin cancer type is the most common malignant tumor throughout the world. The incidence is higher in age over 60. The intense of exposure to ultraviolet radiation is one of the known risk factors. Over 50% of BCC of the periocular region initially occur on the lower lid and inner angle. Literature review of treatment options for basal cell carcinoma, which consist of surgery, or combined techniques plus vismodegib, radiotherapy and imiquimod. The first consideration for treatment of periocular BCC is radical surgical excision using Mohs micrographic technique. Functional and esthetic outcome in patients are important after clear excisions and reconstruction should be carefully considered. Radical exenteration is considered in the case of orbital invasion of high-risk aggressive BCC.

scholarly journals Early Onset Basal Cell Carcinoma: Surgical Approach

2014 ◽  
Vol 41 (1) ◽  
pp. 82-87
Author(s):  
M. Betekhtin ◽  
J. Ananiev ◽  
G. Tchernev ◽  
L. Zisova ◽  
S. Philipov ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Early Onset ◽  
Surgical Excision ◽  
Nasolabial Fold ◽  
Non Melanoma Skin Cancer ◽  
Suitable Treatment ◽  
Excellent Cosmetic Result ◽  
Melanoma Skin

Summary Basal cell carcinoma (BCC) is the most frequent non-melanoma skin cancer. Only 5-15% of BCC cases can be found in patients aged 20-40 years (so-called early onset). The early onset BCC is characterized by active and aggressive tumour growth, clinically presenting in most of the cases as a morpheaform, locally infiltrating or recurrent BCC. Despite the advances in the study of the pathogenesis of this tumour, surgery remains the most used, most effective and most suitable treatment modality. We describe a case of a 39-year-old woman who developed an early onset BCC of the nasolabial fold. After the subsequent surgical excision an excellent cosmetic result was achieved.

Agreement between histological subtype on punch biopsy and surgical excision in primary basal cell carcinoma

2012 ◽  
Vol 27 (7) ◽  
pp. 894-898 ◽  
Author(s):  
M.H. Roozeboom ◽  
K. Mosterd ◽  
V.J.L. Winnepenninckx ◽  
P.J. Nelemans ◽  
N.W.J. Kelleners-Smeets
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Surgical Excision ◽  
Punch Biopsy ◽  
Histological Subtype

Staged excision of primary periocular basal cell carcinoma: absence of residual tumour in re-excised specimens: a 10-year series

2018 ◽  
Vol 103 (7) ◽  
pp. 976-979 ◽  
Author(s):  
Lindsay A McGrath ◽  
Adam Meeney ◽  
Zanna I Currie ◽  
Hardeep Singh Mudhar ◽  
Jennifer H Tan
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Significant Proportion ◽  
Surgical Excision ◽  
Lower Eyelid ◽  
Growth Patterns ◽  
Residual Tumour ◽  
Tumour Characteristics

AimsThe aim is to study staged periocular basal cell carcinoma (BCC) excision in a tertiary oculoplastic referral centre in Sheffield, UK. In particular, we examined patients with close or positive margins and no tumour seen on re-excision to identify demographics and tumour characteristics in this population.MethodsA retrospective review of medical records of 437 cases of staged periocular BCC excisions over a 10-year period (2007–2017) was carried out. Patients had surgical excision with 3 mm clinically clear margins. Staged excision was performed for all cases included in this study. Standard reconstruction techniques were employed. Histopathology was analysed for tumour type, subtype and stage.ResultsOver the 10-year period, of the 437 periocular BCCs, 156 had close or involved margins. Residual tumour was found in 29 (18.6%), whereas in 122 eyelids of 120 patients (78.2%) no residual tumour was identified on histological examination. Micronodular (54.1%) and nodular (23.7%) growth patterns of BCC, as well as lower eyelid location (72.1%), were the most prevalent in this population. Two patients (1.6%) had recurrence of BCC over a mean follow-up of 57 months (range 1–125 months).ConclusionsA significant proportion of BCCs transected on initial excision show no residual tumour in the re-excision specimens. In the interval between initial excision and re-excision, there may be eradication of the residual tumour. The exact mechanisms for this are unclear, however, and re-excision remains the appropriate recommended course in the presence of involved surgical margins of periocular BCC, particularly when high-risk tumour subtypes are encountered.

A review of emerging and non-US FDA-approved topical agents for the treatment of basal cell carcinoma

2021 ◽  
Author(s):  
Natalie Kash ◽  
Sirunya Silapunt
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Gold Standard ◽  
Treatment Options ◽  
Tumor Characteristics ◽  
Tumor Clearance ◽  
Superficial Basal Cell Carcinoma ◽  
Us Fda ◽  
Cure Rates

Although surgical therapy continues to be the gold standard for the treatment of basal cell carcinoma given high cure rates and the ability to histologically confirm tumor clearance, there are a number of nonsurgical treatment options that may be considered based on individual tumor characteristics, functional and cosmetic considerations, patient comorbidities and patient preference. Topical 5-fluorouracil 5% cream and imiquimod 5% cream have been US FDA-approved for the treatment of superficial basal cell carcinoma. Additionally, a number of new and emerging topical agents and techniques have been described for the treatment of basal cell carcinoma and will be reviewed herein.

Sign in / Sign up

Export Citation Format

Share Document